公共卫生学院机构知识库

Institutional Repository, School of Public health

 

兰州大学机构库  > 公共卫生学院  > 期刊论文
题名: Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta- analysis based on 15 studies
作者: Rong, BX; Liu, H; Gao, WL; Yang, SY
收录类别: SCIE
出版日期: 2016-12-27
刊名: ONCOTARGET
卷号: 7, 期号:2-21, 页码:86902-86913
出版者: IMPACT JOURNALS LLC
出版地: ORCHARD PARK
英文摘要: Icotinib is a new epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that developed and used in China; this work was to evaluate its efficacy and safety in treating non-small cell lung cancer (NSCLC). Clinical studies evaluating the efficacy and safety of icotinib in treating NSCLC were identified from the databases of Medline, Web of Science, Embase and Cochrance Library. Pooled efficacy and safety of icotinib were calculated through a series of predefined search strategies. A total of 15 studies with 2,304 patients were involved in this study. The overall response rate (ORR) and disease control rate (DCR) of icotinib were 40.99% (95% CI: 33.77% to 48.22%) and 77.16% (95% CI: 51.43% to 82.31%). The pooled progression-free survival (PFS) and overall survival (OS) were 7.34 months (95% CI: 5.60 to 9.07) and 14.98 months (95% CI: 9.78 to 20.18). Patients with EGFR mutations exhibited better ORR (OR = 3.67, p < 0.001), DCR (OR = 1.39, p = 0.001) and PFS (11.0 +/- 0.76 vs. 1.97 +/- 0.82 months). Moreover, patients with rash had a higher ORR (OR = 2.14, p = 0.001) than those without rash. The common adverse effects (AEs) included skin rash (31.4%), diarrhea (14.2%), pruritus (6.7%) and hepatic toxicity (3.8%) and most of them were well tolerated. In conclusion, Icotinib is an effective and well tolerated regimen for Chinese patients with advanced NSCLC. Further randomized trials with large population are required to provide stronger evidence for icotinib in treating NSCLC.
关键词: icotinib ; non-small cell lung cancer ; NSCLC ; meta-analysis ; efficacy
作者部门: [Rong Biaoxue] Xian Med Univ, Affiliated Hosp 1, Dept Resp Med, Xian, Peoples R China ; [Liu Hua] Gansu Prov Hosp, Dept Resp Med, Lanzhou, Peoples R China ; [Gao Wenlong] Lanzhou Univ, Dept Stat & Epidemiol, Coll Med, Lanzhou, Peoples R China ; [Yang Shuanying] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Resp Med, Xian, Peoples R China
通讯作者: Rong, BX (reprint author), Xian Med Univ, Affiliated Hosp 1, Dept Resp Med, Xian, Peoples R China.
学科分类: Oncology; Cell Biology
文章类型: Article
语种: 英语
DOI: 10.18632/oncotarget.13509
ISSN号: 1949-2553
WOS记录号: WOS:000391422500100
IR记录号: WOS:000391422500100
第一机构:
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.lzu.edu.cn/handle/262010/189120
Appears in Collections:公共卫生学院_期刊论文

Files in This Item:

There are no files associated with this item.


Recommended Citation:
Rong, BX,Liu, H,Gao, WL,et al. Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta- analysis based on 15 studies[J]. ONCOTARGET,2016,7(2-21):86902-86913.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Altmetrics Score
 
Google Scholar
Similar articles in Google Scholar
[Rong, BX]'s Articles
[Liu, H]'s Articles
[Gao, WL]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Rong, BX]‘s Articles
[Liu, H]‘s Articles
[Gao, WL]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Email:
Passwd
验 证:
换一张
Have you forgotten your password? Log In
Copyright © 2007-2017  兰州大学 - Feedback
Powered by CSpace